Related references
Note: Only part of the references are listed.The State of the Art in Colorectal Cancer Molecular Biomarker Testing
Raju K. Pillai et al.
ADVANCES IN ANATOMIC PATHOLOGY (2016)
Treatment strategies for advanced hormone receptor-positive and human epidermal growth factor 2-negative breast cancer: the role of treatment order
Edith A. Perez
DRUG RESISTANCE UPDATES (2016)
Current status of primary pharmacotherapy and future perspectives toward upfront therapy for metastatic hormone-sensitive prostate cancer
Masaki Shiota et al.
INTERNATIONAL JOURNAL OF UROLOGY (2016)
Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial
Andrea Sartore-Bianchi et al.
LANCET ONCOLOGY (2016)
Second-line panitumumab as a triweekly dose for patients with wild-type KRAS exon 2 metastatic colorectal cancer: a single-institution experience
Mohamed A. Daoud et al.
Cancer Biology & Medicine (2016)
Present standards and future perspectives in the treatment of metastatic non-small cell lung cancer
Stefan Zimmermann et al.
CANCER AND METASTASIS REVIEWS (2015)
First-line anti-EGFR monoclonal antibodies in panRAS wild-type metastatic colorectal cancer: A systematic review and meta-analysis
Filippo Pietrantonio et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2015)
Predictive role of BRAF mutations in patients with advanced colorectal cancer receiving cetuximab and panitumumab: A meta-analysis
Filippo Pietrantonio et al.
EUROPEAN JOURNAL OF CANCER (2015)
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
D. T. Le et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Single-Agent Panitumumab in Frail Elderly Patients With Advanced RAS and BRAF Wild-Type Colorectal Cancer: Challenging Drug Label to Light Up New Hope
Filippo Pietrantonio et al.
ONCOLOGIST (2015)
IGF2 is an actionable target that identifies a distinct subpopulation of colorectal cancer patients with marginal response to anti-EGFR therapies
Eugenia R. Zanella et al.
SCIENCE TRANSLATIONAL MEDICINE (2015)
Prospective noninterventional study on the use of panitumumab monotherapy in patients with recurrent or progressive colorectal cancer: the VECTIS study
Radek Lakomy et al.
CANCER MANAGEMENT AND RESEARCH (2015)
Metastatic colorectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
E. Van Cutsem et al.
ANNALS OF ONCOLOGY (2014)
Panitumumab Monotherapy as a Second-line Treatment in Metastasised Colorectal Cancer: A Single Centre Experience
I. E. G. van Hellemond et al.
CLINICAL ONCOLOGY (2014)
How to select the optimal treatment for first line metastatic colorectal cancer
Alexander Stein et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2014)
Optimizing Single Agent Panitumumab Therapy in Pre-Treated Advanced Colorectal Cancer
Giampietro Gasparini et al.
NEOPLASIA (2014)
Detection of EGFR mutations and EML4-ALK rearrangements in lung adenocarcinomas using archived cytological slides
Natalia V. Mitiushkina et al.
CANCER CYTOPATHOLOGY (2013)
Pattern of clinically relevant mutations in consecutive series of Russian colorectal cancer patients
Grigoriy A. Yanus et al.
MEDICAL ONCOLOGY (2013)
Cetuximab as salvage monotherapy in chemotherapy-refractory metastatic colorectal cancer: A single-center report
Eiji Mekata et al.
ONCOLOGY LETTERS (2013)
First-line single-agent cetuximab in elderly patients with metastatic colorectal cancer. A phase II clinical and molecular study of the Spanish group for digestive tumor therapy (TTD)
J. Sastre et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2011)
Retrospective analysis of cetuximab monotherapy for patients with irinotecan-intolerant metastatic colorectal cancer
Ayako Mizota et al.
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY (2011)
A phase II, multicenter study of cetuximab monotherapy in patients with refractory, metastatic colorectal carcinoma with absent epidermal growth factor receptor immunostaining
Rafal Wierzbicki et al.
INVESTIGATIONAL NEW DRUGS (2011)
The role of anti-epidermal growth factor receptor monoclonal antibody monotherapy in the treatment of metastatic colorectal cancer
Olivier Bouche et al.
CANCER TREATMENT REVIEWS (2010)
Lack of Correlation between Epidermal Growth Factor Receptor Status and Response to Panitumumab Monotherapy in Metastatic Colorectal Cancer
J. Randolph Hecht et al.
CLINICAL CANCER RESEARCH (2010)
A Phase 2 Clinical Trial of Panitumumab Monotherapy in Japanese Patients with Metastatic Colorectal Cancer
Kei Muro et al.
JAPANESE JOURNAL OF CLINICAL ONCOLOGY (2009)
Anti-Epidermal Growth Factor Receptor Monotherapy in the Treatment of Metastatic Colorectal Cancer: Where Are We Today?
Marc Peeters et al.
ONCOLOGIST (2009)
Sequential versus combination therapy in the treatment of patients with advanced colorectal cancer
Usman Shah et al.
CLINICAL COLORECTAL CANCER (2008)
First-line single-agent cetuximab in patients with advanced colorectal cancer
A. Pessino et al.
ANNALS OF ONCOLOGY (2008)
Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry
KY Chung et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Share Paper
